Palatin Technologies, Inc. (NYSE Amex: PTN) is a biopharmaceutical company focused on the development of targeted therapeutics that modulate the activity of the melanocortin and natriuretic peptide receptor systems. Their lead program is bremelanotide, a melanocortin receptor agonist for the treatment of female sexual dysfunction (FSD). Palatin completed a successful Phase IIb trial in patients with FSD that met the primary endpoint and key secondary endpoints. A Phase III clinical program has been designed and the first trial is expected to begin in the first half of 2014. Palatin has additional drug candidates or development programs for obesity, erectile dysfunction, pulmonary diseases, cardiovascular diseases and inflammatory diseases. Several highly specific MC4R agonists for the treatment of obesity and diabetes have been licensed to AstraZeneca. PL-6983 is an MC4R agonist being developed internally by Palatin as a next-generation treatment for use in both FSD and erectile dysfunction (ED). Palatin is actively conducting preclinical research to identify a melanocortin receptor 1 (MC1R) agonist for potential use in dermatologic and inflammatory disease indications. PL-3994 is a natriuretic peptide receptor A (NPRA) agonist and has been tested in Phase 1 and Phase 2a clinical trials that shows promise as a therapeutic for both acute severe asthma and cardiovascular indications.